We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




AI Diagnostic Tool Analyzes CT Scans to Spot Prostate Cancer Before Patients Have Symptoms

By HospiMedica International staff writers
Posted on 13 Jul 2021
Researchers have developed a diagnostic tool that can spot prostate cancer before patients have any symptoms, using artificial intelligence to analyze Computed Tomography (CT) scans in just seconds.

Researchers at RMIT University (Melbourne, Australia), in collaboration with clinicians at St Vincent’s Hospital Melbourne (Australia), have developed an artificial intelligence (AI) program that could catch the prostate cancer earlier, allowing for incidental detection through routine CT scans. More...
The technology works by analyzing CT scans for tell-tale signs of prostate cancer, something even a well-trained human eye struggles to do.

Prostate cancer is the most diagnosed cancer and is slow growing, usually detected incidentally due to which it can go undiagnosed for years. It was responsible for an estimated 12% of male cancer deaths in 2020. Early detection is the key to successful treatment but men often dodge the doctor, avoiding diagnosis tests until it’s too late. CT imaging is not suitable for regular cancer screening because of the high radiation doses involved. CT scans were great for detecting bone and joint problems but even radiologists struggled to spot prostate cancers on the images. The new AI solution can be used to run a cancer check whenever men have their abdomen or pelvis scanned for other issues.

For the study, the researchers studied CT scans of asymptomatic patients, with and without prostate cancer. The team trained the AI software to look for features of disease in a variety of scans and where exactly to look for them, avoiding the need to manually crop the images. The AI performed better than radiologists who viewed the same images, detecting cancerous growths in just seconds. What’s more, the AI improved with each scan, learning and adapting to read images from different machines to spot even the smallest irregularities. The technology can be applied at scale, potentially integrating with a variety of diagnostic imaging equipment like MRI and DEXA machines - pending further research.

“We’ve trained our software to see what the human eye can’t, with the aim of spotting prostate cancer through incidental detection,” said RMIT’s Dr. Ruwan Tennakoon. “It’s like training a sniffer dog – we can teach the AI to see things that we can't with our own eyes, in the same way a dog can smell things human noses can’t.”

Related Links:
RMIT University
St Vincent’s Hospital Melbourne



Gold Member
12-Channel ECG
CM1200B
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Hybrid Arch Device
Neo EDE
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Masimo smartSET pulse oximetry with PPG AFib and OIRD Detection (Photo courtesy of Masimo)

Smart Pulse Oximetry Supports Earlier Recognition of Arrhythmias and Respiratory Risk

On general care floors, respiratory compromise and arrhythmias can develop between routine checks. Atrial fibrillation often goes undiagnosed in older adults, while opioid-induced respiratory depression... Read more

Surgical Techniques

view channel
Image: A UTSW clinical trial studied a treatment strategy for kidney cancer with inferior vena cava tumor thrombus (IVC-TT) that used targeted radiation on the tumor thrombus followed by surgery to remove the kidney. (Photo courtesy of UT Southwestern)

Targeted Radiotherapy Before Surgery Improves Control of Kidney Cancer Thrombus

Inferior vena cava tumor thrombus occurs when kidney cancer extends into the body’s largest vein, potentially obstructing blood flow, progressing toward the heart, and making surgery more complex.... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.